title: Adolescent cannabinoid exposure permanently suppresses cortical oscillations in adult mice.
abstract: Regular marijuana use during adolescence, but not adulthood, may permanently impair cognition and increase the risk for psychiatric diseases, such as schizophrenia. Cortical oscillations are integral for cognitive processes and are abnormal in patients with schizophrenia. We test the hypothesis that adolescence is a sensitive period because of the active development of cortical oscillations and neuromodulatory systems that underlie them. The endocannabinoid system upon which marijuana acts is one such system. Here we test the prediction that adolescent cannabinoid exposure alters cortical oscillations in adults. Using in vitro local field potential, in vivo electrocorticogram recordings and cognitive behavioral testing in adult mice, we demonstrate that chronic adolescent, but not adult, cannabinoid exposure suppresses pharmacologically evoked cortical oscillations and impairs working memory performance in adults. The later-maturing prefrontal cortex is more sensitive to adolescent exposure than the earlier-maturing, primary somatosensory cortex. These data establish a link between chronic adolescent cannabinoid exposure and alterations in adult cortical network activity that underlie cognitive processes.
authors.affiliation: 1] Program in Neuroscience, University of Maryland School of Medicine, Baltimore, MD, USA [2] Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA.
authors.forename: Sylvina M
authors.initials: SM
authors.lastname: Raver
authors.forename: Sarah P
authors.initials: SP
authors.lastname: Haughwout
authors.forename: Asaf
authors.initials: A
authors.lastname: Keller
mesh_terms: D000367:Age Factors; D000818:Animals; D048588:Benzoxazines / Q000494:pharmacology / Q000633:toxicity; D058256:Brain Waves / Q000187:drug effects* / Q000502:physiology; D063386:Cannabinoid Receptor Agonists / Q000494:pharmacology / Q000633:toxicity; D002186:Cannabinoids / Q000633:toxicity*; D002540:Cerebral Cortex / Q000187:drug effects* / Q000254:growth & development / Q000502:physiology; D013759:Dronabinol / Q000494:pharmacology / Q000633:toxicity; D004569:Electroencephalography; D005106:Exploratory Behavior / Q000187:drug effects / Q000502:physiology; D008297:Male; D051379:Mice; D009025:Morpholines / Q000494:pharmacology / Q000633:toxicity; D009281:Naphthalenes / Q000494:pharmacology / Q000633:toxicity; D021641:Recognition, Psychology / Q000187:drug effects / Q000502:physiology
chemical_list: D048588:Benzoxazines; D063386:Cannabinoid Receptor Agonists; D002186:Cannabinoids; D009025:Morpholines; D009281:Naphthalenes; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D013759:Dronabinol